UK: Treatment guides for treating kidney and prostate cancer

Final guidance on use of axitinib for treating kidney cancer and sipuleucel-T for prostate cancer. Guidance issued to the NHS today, recommends that the drug axitinib, known as Inlyta by Pfizer, should be available as a second line treatment for kidney cancer. A separate new guide did not recommended sipuleucel-T, known as Provenge, for treating…

Read More

Prostate cancer treatment too expensive!

Sipuleucel-T cost too high for prostate cancer patients Final draft guidance not recommending sipuleucel-T for use with: Prostate cancer in men whose disease has spread, Who have few symptoms and with disease not yet suitable for chemotherapy treatment. Evidence showed price to NHS too high for potential benefit it may provide to patients. Sipuleucel-T, known…

Read More